CDKN2A and cancer: Inhibiting DNA methyltransferases can lead to increased methylation in the CpG-rich promoter regions of cyclin-dependent kinase inhibitor A (CDKN2A), inducing the expression of INK4A and ARF, which results in cancer cell senescence [101].